Janus Henderson Global Life Sciences I2 USD (IE0002141913)
77.13
+0.07
(+0.09%)
USD |
Apr 22 2026
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| -- | -- | -- | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -- | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Broad Asset Class | None |
| Broad Category | None |
| Global Peer Group | None |
| Peer Group | None |
| Global Macro | None |
| US Macro | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | None |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
--
--
Peer Group Low
--
Peer Group High
1 Year
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
6 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
5 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
YTD
% Rank:
--
--
Peer Group Low
--
Peer Group High
10 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of April 23, 2026.
Asset Allocation
| Type | % Net |
|---|---|
| Cash | -- |
| Stock | -- |
| Bond | -- |
| Convertible | -- |
| Preferred | -- |
| Other | -- |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 8.86% | 916.27 | -0.57% |
| Johnson & Johnson | 7.31% | 230.25 | 1.84% |
| AstraZeneca PLC | 4.60% | 194.83 | 0.01% |
| AbbVie, Inc. | 4.07% | 201.45 | 0.47% |
| UnitedHealth Group, Inc. | 3.14% | 354.04 | 0.15% |
| Novartis AG | 2.86% | 147.79 | 0.32% |
| Thermo Fisher Scientific, Inc. | 2.51% | 460.72 | -10.36% |
| Praxis Precision Medicines, Inc. | 2.46% | 340.22 | 0.87% |
| argenx SE | 2.41% | 798.12 | 0.62% |
| Abbott Laboratories | 2.40% | 91.30 | -0.44% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors | -- |
| Minimum Initial Investment | -- |
| Minimum Subsequent Investment | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Broad Asset Class | None |
| Broad Category | None |
| Global Peer Group | None |
| Peer Group | None |
| Global Macro | None |
| US Macro | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | None |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM | -- |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| ROI (TTM) | -- |
| Return on Investment (TTM) | -- |
| Earning Yield | -- |
| LT Debt / Shareholders Equity | -- |
| Number of Equity Holdings | -- |
Growth Metrics
| EPS Growth (1Y) | -- |
| EPS Growth (3Y) | -- |
| EPS Growth (5Y) | -- |
| Sales Growth (1Y) | -- |
| Sales Growth (3Y) | -- |
| Sales Growth (5Y) | -- |
| Sales per Share Growth (1Y) | -- |
| Sales per Share Growth (3Y) | -- |
| Operating Cash Flow - Growth Rate (3Y) | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Last Annual Report Date | -- |
| Last Prospectus Date | -- |
| Share Classes | |
| IE0002122038 | -- |
| IE0002128837 | -- |
| IE0008I0JXW0 | -- |
| IE0009355771 | -- |
| IE000G3N3NE7 | -- |
| IE000KJSGS14 | -- |
| IE000RUGMMJ8 | -- |
| IE000XWBFHZ3 | -- |
| IE000YTZ5BP2 | -- |
| IE00B2B36G96 | -- |
| IE00B2B36J28 | -- |
| IE00B3S2VD85 | -- |
| IE00B4R5TH58 | -- |
| IE00B613WX69 | -- |
| IE00B6QFF942 | -- |
| IE00B8GQ0T69 | -- |
| IE00BF2GM042 | -- |
| IE00BFRSYJ83 | -- |
| IE00BFRSYK98 | -- |
| IE00BFTCP959 | -- |
| IE00BFTCPJ56 | -- |
| IE00BJJMRZ35 | -- |
| IE00BJT1NW94 | -- |
| IE00BMXMTZ48 | -- |
| IE00BMXMV038 | -- |
| IE00BMXMV145 | -- |
| IE00BRJ9D748 | -- |
| IE00BRJG6X20 | -- |
| IE00BRJG6Y37 | -- |
| IE00BRJG7840 | -- |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | -- |
| Leveraged Fund | -- |
| Fund of Funds | -- |
| Currency Hedged Fund | -- |
| Socially Responsible Fund | -- |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:IE0002141913", "name") |
| Broad Asset Class: =YCI("M:IE0002141913", "broad_asset_class") |
| Broad Category: =YCI("M:IE0002141913", "broad_category_group") |
| Prospectus Objective: =YCI("M:IE0002141913", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |